SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Economist Intelligence Unit report, sponsored by Livestrong. Breakaway: The global burden of cancer—challenges and opportunities. http://www.livestrong.org/pdfs/GlobalEconomicImpact. August 2009.
  • 2
    Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:16871717.
  • 3
    Love RR, Van Dinh N, Quy TT, et al. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. J Clin Oncol. 2008;26:253257.
  • 4
    Robert H, Wang M, Cella D, et al. Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node negative receptor-positive breast cancer ≤ 3 cm [Abstract]. Proc Am Soc Clin Oncol. 2003;22:5 (abstract 16).
  • 5
    Davidson NE, O'Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188). J Clin Oncol. 2005;23:59735982.
  • 6
    Klijn JG, Beex LV, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomised study. J Natl Cancer Inst. 2000;92:903911.
  • 7
    Klijn JGM, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol. 2001;19:343353.
  • 8
    Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:17111723.
  • 9
    Parton M, Smith IE. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women. J Clin Oncol. 2008;26:745762.
  • 10
    Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacologic intervention to prevent fractures. Arch Int Med. 2004;164:11081112.
  • 11
    WHO Scientific Group. Prevention and Management of Osteoporosis. WHO Technical Report Series 921. Geneva, Switzerland: World Health Organization; 2003.
  • 12
    Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852856.
  • 13
    Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:7884.
  • 14
    Eastell R, Admas J, Glack G, et al. Long term effects of anastrozole on bone mineral density: 7 year results from the ATC trial. Ann Oncol. 2011;22:857862.
  • 15
    Sverrisdottir A, Fortnander H, Jabcobsson H, von Schoultz E, Rutqvist LE. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol. 2004;22:36943699.
  • 16
    Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25:820828.
  • 17
    Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in premenopausal women with early stage breast cancer. J Clin Oncol. 2001;19:33063311.
  • 18
    Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998;90:704708.
  • 19
    Saarto T, Blomqvist C, Valimaki M, et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997;15:13411347.
  • 20
    Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double blind, placebo-controlled study. J Clin Oncol. 1997;15:955962.
  • 21
    Stevens W. Asymptotic regression. Biometrics. 1951;7:247267.
  • 22
    Love RR, Duc NB, Dinh NV, et al. Mastectomy and oophorectomy by menstrual cycle phase in operable breast cancer. J Natl Cancer Inst. 2002;94:662669.
  • 23
    Love RR, Duc NB, Havighurst TC, et al. HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol. 2003;21:453457.